Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review

Kipshidze, Nicholas; Iversen, Patrick; Porter, Thomas R.; Kipshidze, Nodar; Siddiqui, Fakiha; Dangas, George; Fareed, Jawed

doi:10.1177/1076029620954911

Cited by 11 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within the viral protein, both structural proteins and non-structural proteins of the virus lies. For example, spike glycoprotein were the structural proteins that permit the viral compounds to attach themselves to the host cell ACE-2 receptor, (NSP-15, NSP-9) the non-structural proteins ease viral replication and along with these proteases inflect the manufacturing of diverse proteins via proteolytic cleavage [18,19]. In this study, our main objective was to achieve novel drug aspirants that comprise of three main characters one should retain their competent pharmacokinetic properties with the least toxicity, and to assure safety all along administration and must possess remarkable competency to interact with the targeted site of these viral proteins.…”

Section: Discussionmentioning

confidence: 99%

Virtual Screening of Inhibitory Agents Against SARS-CoV2

M¹,

Bilal²,

Khan³

et al. 2021

Preprint

View full text Add to dashboard Cite

<div>Severe Acute Respiratory Syndrome (SARS-CoV2) infected about 93 million people and killed over two million worldwide. The disease transmits very quickly, therefore; due to its severity and widespread the World Health Organization has declared this menace as ‘Global Pandemic’. An urgent need was felt to manage this disease through aggressive and efficient research process all over the globe. That’s why drug re-purposing of 212 chemical entities (CEs) against SARS-COV2 was found to be one of the efficient ways in finding new indications of already discovered drugs amisdst of the discovery of a new drug. Results of this study revealed that out of 212 CEs, only Etodolac forms a hydrogen (H)-bond with a relatively low energy and active central fragment, demonstrating more significant interaction with SARS-CoV2 viral proteins. Other CEs exhibit good pharmacokinetics properties with the least acute toxicity through ADMET analysis. We also discovered other therapeutic applications of these CEs through Molinspiration. Etodolac, a non-steroidal anti-inflammatory drug forms H-bonding with 5.6 kcal/mol binding energy with active residues of this receptor. This drug created H-bonding with PHE326 and PRO328, with pyridine group, and was found more suitable to control SARS-CoV2.</div>

show abstract

Section: Discussionmentioning

confidence: 99%

Virtual Screening of Inhibitory Agents Against SARS-CoV2

M¹,

Bilal²,

Khan³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Moreover, inhalation allows for rapid onset of action and high dose to the lung while minimizing systemic exposure. [36,37] We, therefore, conducted an in vivo short-term lung toxicity study in mice to evaluate the safety of the anti-ACE2 peptides after intratracheal administration at a dose of 2 mg kg −1 . After 72 h, the lungs were harvested for histological analysis.…”

Section: Cell Toxicity and Stability Studiesmentioning

confidence: 99%

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity

Adhikary

Kandel

Mamani

et al. 2021

Advanced Therapeutics

View full text Add to dashboard Cite

COVID‐19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which infects host cells by binding its viral spike protein receptor‐binding domain (RBD) to the angiotensin converting enzyme 2 (ACE2) on host cells. Blocking the SARS‐CoV‐2‐RBD/ACE2 interaction is, therefore, a potential strategy to inhibit viral infections. Using a novel biopanning strategy, a small anti‐ACE2 peptide is discovered, which shows high affinity and specificity to human ACE2. It blocks not only the SARS‐CoV‐2‐RBD/ACE2 interaction but also the SARS‐CoV‐1‐RBD/ACE2 interaction. Moreover, it inhibits SARS‐CoV‐2 infection in Vero‐E6 cells. The peptide shows negligible cytotoxicity in Vero‐E6 cells and Huh7 cells. In vivo short‐term lung toxicity study also demonstrates a good safety of the peptide after intratracheal administration. The anti‐ACE2 peptide can be potentially used as a prophylactic or therapeutic agent for SARS‐CoV‐2 or other ACE2‐mediated viruses. The strategy used in this study also provides a fast‐track platform to discover other antiviral peptides, which will prepare the world for future pandemics.

show abstract

“…This approach could expand the application of already established drugs to reduce the mortality of this devastating disease. 223 …”

Section: Conclusion and Future Outlookmentioning

confidence: 99%

Review of Oxygenation with Nanobubbles: Possible Treatment for Hypoxic COVID-19 Patients

Afshari

Akhavan

Hamblin

et al. 2021

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) pandemic, which has spread around the world, caused the death of many affected patients, partly because of the lack of oxygen arising from impaired respiration or blood circulation. Thus, maintaining an appropriate level of oxygen in the patients’ blood by devising alternatives to ventilator systems is a top priority goal for clinicians. The present review highlights the ever-increasing application of nanobubbles (NBs), miniature gaseous vesicles, for the oxygenation of hypoxic patients. Oxygen-containing NBs can exert a range of beneficial physiologic and pharmacologic effects that include tissue oxygenation, as well as tissue repair mechanisms, antiinflammatory properties, and antibacterial activity. In this review, we provide a comprehensive survey of the application of oxygen-containing NBs, with a primary focus on the development of intravenous platforms. The multimodal functions of oxygen-carrying NBs, including antimicrobial, antiinflammatory, drug carrying, and the promotion of wound healing are discussed, including the benefits and challenges of using NBs as a treatment for patients with acute hypoxemic respiratory failure, particularly due to COVID-19.

show abstract

Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review

Cited by 11 publications

References 22 publications

Virtual Screening of Inhibitory Agents Against SARS-CoV2

Virtual Screening of Inhibitory Agents Against SARS-CoV2

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity

Review of Oxygenation with Nanobubbles: Possible Treatment for Hypoxic COVID-19 Patients

Contact Info

Product

Resources

About